Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating reissued by equities researchers at Numis Securities Ltd in a research report issued to clients and investors on Tuesday. They presently have a GBX 45 ($0.59) price target on the stock. Numis Securities Ltd’s price target indicates a potential upside of 74.76% from the stock’s current price.

A number of other brokerages have also recently commented on AGY. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 60 ($0.78) target price on shares of Allergy Therapeutics plc in a report on Tuesday, April 4th. FinnCap raised their target price on Allergy Therapeutics plc from GBX 43 ($0.56) to GBX 46 ($0.60) and gave the stock a “buy” rating in a report on Tuesday. Finally, Panmure Gordon reaffirmed a “buy” rating and issued a GBX 53 ($0.69) target price on shares of Allergy Therapeutics plc in a report on Thursday, April 20th.

Allergy Therapeutics plc (LON AGY) opened at 25.75 on Tuesday. The stock’s market capitalization is GBX 152.81 million. Allergy Therapeutics plc has a 12 month low of GBX 17.25 and a 12 month high of GBX 31.00. The stock has a 50 day moving average price of GBX 26.26 and a 200 day moving average price of GBX 25.56.

TRADEMARK VIOLATION WARNING: “Allergy Therapeutics plc (AGY) Earns “Buy” Rating from Numis Securities Ltd” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at

About Allergy Therapeutics plc

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Stock Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related stocks with our FREE daily email newsletter.